華潤雙鶴(600062.SH):浙江新賽科左乙拉西坦原料藥通過GMP認證
格隆匯11月26日丨華潤雙鶴(600062.SH)公佈,近日,公司下屬公司浙江新賽科藥業有限公司(以下簡稱“浙江新賽科”)收到浙江省藥品監督管理局頒發的左乙拉西坦原料藥《藥品GMP證書》。本次認證為原料藥(左乙拉西坦)首次GMP認證,為浙江新賽科生產常態化標準迎接認證,未投入相關費用。
該產品獲得《藥品GMP證書》後可銷售至國內市場,豐富了公司產品結構,可帶來新的利潤增長點。本次獲得《藥品GMP證書》是對浙江新賽科質量體系和生產能力的肯定,有利於進一步提高公司產品質量和生產能力,滿足市場需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.